Evidence map›Paper›PMID 41050432›Full record

ArticleCase reports in oncological medicine2025

A Critical Case of Chronic Eosinophilic Leukemia: Diagnostic Criteria and Response to Cytarabine.

Ana Karen Cruz-Acevedo, Eduardo L Pérez-Campos, María Teresa Hernández-Huerta, Miguel Cruz-Reyes, Joel López-Matías, Laura Pérez-Campos Mayoral, Víctor Cruz-Hernández

Abstract readCase Reports
In one paragraph

Article in Case reports in oncological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ana Karen Cruz-AcevedoResearch Centre-Faculty of Medicine, National Autonomous University of Mexico-Benito Juárez Autonomous University of Oaxaca, Oaxaca, Mexico.
Eduardo L Pérez-CamposNational Technological of Mexico, Technological Institute of Oaxaca, Oaxaca, Mexico.
María Teresa Hernández-HuertaSecretariat of Science, Humanities, Technology and Innovation SECIHTI, Faculty of Medicine, Benito Juárez Autonomous University of Oaxaca, Oaxaca, Mexico.
Miguel Cruz-ReyesInternal Medicine Department, General Hospital Dr. "Aurelio Valdivieso" IMSS-Bienestar, Oaxaca, Mexico.ORCID https://orcid.org/0009-0000-4723-577X
Joel López-MatíasInternal Medicine Department, General Hospital Dr. "Aurelio Valdivieso" IMSS-Bienestar, Oaxaca, Mexico.ORCID https://orcid.org/0009-0000-2531-5824
Laura Pérez-Campos MayoralResearch Centre-Faculty of Medicine, National Autonomous University of Mexico-Benito Juárez Autonomous University of Oaxaca, Oaxaca, Mexico.ORCID https://orcid.org/0000-0003-4140-4661
Víctor Cruz-HernándezInternal Medicine Department, General Hospital Dr. "Aurelio Valdivieso" IMSS-Bienestar, Oaxaca, Mexico.ORCID https://orcid.org/0000-0003-2798-3716

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic eosinophilic leukemia (CEL) belongs to the group of chronic myeloproliferative neoplasms characterized by the persistence of an absolute eosinophil count (AEC) > 1.5 × 10

Indexed as

cytarabinecytarabine responsecytogenetic alterationsmyeloproliferative neoplasmsorgan damageulcerative lesions

Identifiers

PMID41050432
PMCPMC12496144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.